Medical device company Vitrolife AB (STO:VITR) announced on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in the US, considered the world's third largest market measured in terms of number of IVF treatments.
EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients. Vitrolife is a market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.
With this approval, Vitrolife will be able to offer EmbryoScope+ to clinics in US.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project